Cost-effectiveness of upfront vs delayed allogeneic hematopoietic stem cell transplant for intermediate risk AML

Abstract: The ETAL-1 trial demonstrated that upfront allogeneic hematopoietic stem cell transplant (HSCT) improved disease-free survival, but not overall survival, when compared with consolidation chemotherapy followed by “delayed” HSCT on relapse in patients with intermediate-risk acute myeloid leu...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Abdulrahman Alhajahjeh, Kishan K. Patel, Nikolai A. Podoltsev, Tariq Kewan, Jessica M. Stempel, Lourdes Mendez, Stuart Seropian, Lohith Gowda, Scott F. Huntington, Maximilian Stahl, Amer M. Zeidan, George Goshua, Jan Philipp Bewersdorf
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2025-10-01
coleção:	Blood Advances
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2473952925004446
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!